Institute for Quality and Efficiency in Health Care Dec 27 2024 Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined in an early benefit assessment whether faricimab offers patients benefits over ranibizumab or aflibercept. However, the drug manufacturer did not present any suitable data. Consequently,